A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea
Status:
Not yet recruiting
Trial end date:
2022-12-09
Target enrollment:
Participant gender:
Summary
The main aim of the study is to check the side effects from overnight treatment with
danavorexton and assess the tolerability of varying doses of danavorexton administered
intravenously.
Before starting treatment with danavorexton, participants will keep a sleep diary and use an
under-mattress sensor for at least 7 nights to check regular sleep habits.
There will be 3 Treatment Period up to 12 days apart. In each Treatment Period, participants
will receive an intravenous (through the vein) infusion of either danavorexton or a placebo
starting in the evening and continuing over a 10-hour period. A placebo looks exactly like
danavorexton but does not have any medicine in it.
Participants will take part in a follow-up phone appointment about a week after the last
Treatment Period.